The 2016 Olympic Games are due to begin in Rio de Janeiro this weekend. In the lead-up to this year’s Games, the Zika virus has never been far from the headlines. A number of top golfers and basketball players have decided to pull out and other athletes have also expressed their concerns, despite the risk to anyone who is not pregnant being minimal. As it is not currently mosquito season in Brazil, experts say the Olympics will not accelerate the spread of the virus.
It is thought the epidemic has reached its peak in Latin America and will slowly burn out over the next few years. Still, there have been over 60,000 confirmed cases of the Zika virus in Brazil since the outbreak began in early 2015 and the virus has reached Europe, with the first baby with Zika-related microcephaly born in Spain. Mosquitoes in Florida have now also been seen to transmit the virus, and the Centers for Disease Control and Prevention (CDC) in the US have issued a travel warning for Florida.
The Zika virus remains a prominent public health concern and a priority for the biosciences. In March, EARA spoke to Dr Koen van Rompay, who helped to develop and test the anti-viral drug tenofovir, which is currently the most frequently used HIV drug in the world. We interviewed him on the day before he and his team at the California National Primate Research Center (CNPRC) infected two female rhesus macaques with Zika virus to understand how the disease progresses. We asked him about his current study on the Zika virus, why he uses primate models in his work and how he responds to critics of animal research. Continue reading